LMRINasdaqServices-Medical LaboratoriesFiscal year ends December 31

Lumexa Imaging Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$10.72−0.06 (-0.56%)

Close on Oct 19, 2026

Market cap: $1.03B
P/E (TTM): –
Dividend yield: –

Lumexa Imaging Holdings, Inc. income statement

Annual data is not available for this company.

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	264	253	251	245
General & Administrative	24	20	19	17
Operating Expenses	260	248	240	235
Operating Income	23	19	28	26
Interest Expense	16	16	30	30
Income from Equity Investments	19	15	17	15
Other Non-Operating Income	-17	–	-30	–
Gain (Loss) on Sale of Assets	0.02	-0.14	-0.02	0.16
Pretax Income	5.77	3.08	-2.42	-4.31
Income Tax Expense	3.02	1.36	4.81	3.38
Net Income	2.75	1.72	-7.23	-7.69
EPS (Basic)(per share)	0.03	0.02	-0.10	-0.11
EPS (Diluted)(per share)	0.03	0.02	-0.10	-0.11
Shares Outstanding (Basic, Weighted)(shares)	96	96	70	70
Shares Outstanding (Diluted, Weighted)(shares)	96	96	70	70
EBITDA	33	29	37	35

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 1.44
Debt to equity: 1.36
Debt to assets: 46.1%
Cash to current liabilities: 39.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.67
Dividend yield: –